Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Terms of Use
Privacy Policy
Sitemap
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Pediatric Oncology
ASCO 2022
Questions discussed in this category
In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?
J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024
2 Answers available
13106
Papers discussed in this category
Pediatr Blood Cancer, 2022 Oct 02
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Clin Cancer Res, 2023 Jan 09
Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial.
Related Topics in Pediatric Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers